KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2017 - 2023)

Teva Pharmaceutical Industries' Short-Term Debt issuances history spans 6 years, with the latest figure at $700.0 million for Q3 2023.

  • For the quarter ending Q3 2023, Short-Term Debt issuances changed N/A year-over-year to $700.0 million, compared with a TTM value of $700.0 million through Dec 2024, down 22.22%, and an annual FY2023 reading of $700.0 million, changed N/A over the prior year.
  • Short-Term Debt issuances for Q3 2023 was $700.0 million at Teva Pharmaceutical Industries, up from $200.0 million in the prior quarter.
  • The five-year high for Short-Term Debt issuances was $700.0 million in Q3 2023, with the low at -$1.0 million in Q1 2019.
  • Average Short-Term Debt issuances over 4 years is $245.6 million, with a median of $200.0 million recorded in 2021.
  • Year-over-year, Short-Term Debt issuances surged 9900.0% in 2019 and then crashed 37.3% in 2021.
  • Tracing TEVA's Short-Term Debt issuances over 4 years: stood at $404.0 million in 2019, then fell by 21.04% to $319.0 million in 2020, then tumbled by 37.3% to $200.0 million in 2021, then soared by 250.0% to $700.0 million in 2023.
  • Per Business Quant, the three most recent readings for TEVA's Short-Term Debt issuances are $700.0 million (Q3 2023), $200.0 million (Q4 2021), and $319.0 million (Q4 2020).